ORN News and Press, Orion Group Holdings Inc. Common From 06/18/24

Orion Group Holdings, Inc. (NYSE: ORN) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.25% on the day to $10.44. Orion Group Holdings, Inc. operates as a specialty construction company in the building, industrial, and infrastructure sectors in the continental Un...

Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...

Orion Group Holdings, Inc. (NYSE: ORN) is the focus of IBN's latest stock spotlight. The company's shares have moved -2% on the day to $10.04. Orion Group Holdings, Inc. operates as a specialty construction company in the building, industrial, and infrastructure sectors in the continental Unit...

The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) The combination showed substantial antileukemic activity with deep responses and a manageable safety profile, including in patients with...

Orion Group Holdings, Inc. (NYSE: ORN) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.21% on the day to $10.29. Orion Group Holdings, Inc. operates as a specialty construction company in the building, industrial, and infrastructure sectors in the continental Un...

Orion Group Holdings, Inc. (NYSE: ORN) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.53% on the day to $10.21. Orion Group Holdings, Inc. operates as a specialty construction company in the building, industrial, and infrastructure sectors in the continental Un...

BIO International Convention 2024 European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical ...

Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases MADRID, Spain and CAMBRIDGE, Mass....

HOUSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell indexes annual reconstit...

HOUSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that CEO Travis Boone and CFO Scott Thanisch will participate in the following upcoming conferences: B. Riley Securitie...